JP2010513285A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010513285A5 JP2010513285A5 JP2009541404A JP2009541404A JP2010513285A5 JP 2010513285 A5 JP2010513285 A5 JP 2010513285A5 JP 2009541404 A JP2009541404 A JP 2009541404A JP 2009541404 A JP2009541404 A JP 2009541404A JP 2010513285 A5 JP2010513285 A5 JP 2010513285A5
- Authority
- JP
- Japan
- Prior art keywords
- aliphatic
- optionally
- independently
- cycloaliphatic
- halo
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000001931 aliphatic group Chemical group 0.000 claims 31
- 150000001875 compounds Chemical class 0.000 claims 21
- 125000005843 halogen group Chemical group 0.000 claims 13
- 229910052799 carbon Inorganic materials 0.000 claims 12
- 229910052739 hydrogen Inorganic materials 0.000 claims 12
- 125000002950 monocyclic group Chemical group 0.000 claims 12
- 239000003814 drug Substances 0.000 claims 11
- 125000005842 heteroatom Chemical group 0.000 claims 8
- 229910052757 nitrogen Inorganic materials 0.000 claims 8
- 229910052760 oxygen Inorganic materials 0.000 claims 8
- 229910052717 sulfur Inorganic materials 0.000 claims 8
- 125000003118 aryl group Chemical group 0.000 claims 7
- 125000006367 bivalent amino carbonyl group Chemical group [H]N([*:1])C([*:2])=O 0.000 claims 6
- 229920006395 saturated elastomer Polymers 0.000 claims 6
- 125000004432 carbon atom Chemical group C* 0.000 claims 5
- 102000001253 Protein Kinase Human genes 0.000 claims 4
- 125000004429 atom Chemical group 0.000 claims 4
- 239000003795 chemical substances by application Substances 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 229940079593 drug Drugs 0.000 claims 4
- 238000004519 manufacturing process Methods 0.000 claims 4
- 108060006633 protein kinase Proteins 0.000 claims 4
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 claims 3
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 claims 3
- 208000035475 disorder Diseases 0.000 claims 3
- 125000000623 heterocyclic group Chemical group 0.000 claims 3
- 229940124597 therapeutic agent Drugs 0.000 claims 3
- 102100031463 Serine/threonine-protein kinase PLK1 Human genes 0.000 claims 2
- 125000000217 alkyl group Chemical group 0.000 claims 2
- 239000012472 biological sample Substances 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 210000003169 central nervous system Anatomy 0.000 claims 2
- 125000004122 cyclic group Chemical group 0.000 claims 2
- 239000002552 dosage form Substances 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 108010056274 polo-like kinase 1 Proteins 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims 1
- 125000006714 (C3-C10) heterocyclyl group Chemical group 0.000 claims 1
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 208000019838 Blood disease Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- -1 C 3-6 cycloaliphatic Chemical group 0.000 claims 1
- 125000000041 C6-C10 aryl group Chemical group 0.000 claims 1
- 208000024172 Cardiovascular disease Diseases 0.000 claims 1
- 206010008342 Cervix carcinoma Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000029462 Immunodeficiency disease Diseases 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 108010025020 Nerve Growth Factor Proteins 0.000 claims 1
- 102000007072 Nerve Growth Factors Human genes 0.000 claims 1
- 206010029260 Neuroblastoma Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 239000002260 anti-inflammatory agent Substances 0.000 claims 1
- 229940121363 anti-inflammatory agent Drugs 0.000 claims 1
- 230000001028 anti-proliverative effect Effects 0.000 claims 1
- 239000003443 antiviral agent Substances 0.000 claims 1
- 208000037979 autoimmune inflammatory disease Diseases 0.000 claims 1
- 210000000988 bone and bone Anatomy 0.000 claims 1
- 201000010881 cervical cancer Diseases 0.000 claims 1
- 230000000973 chemotherapeutic effect Effects 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 230000006378 damage Effects 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 208000014951 hematologic disease Diseases 0.000 claims 1
- 208000018706 hematopoietic system disease Diseases 0.000 claims 1
- 125000001072 heteroaryl group Chemical group 0.000 claims 1
- 239000002955 immunomodulating agent Substances 0.000 claims 1
- 229940121354 immunomodulator Drugs 0.000 claims 1
- 229960003444 immunosuppressant agent Drugs 0.000 claims 1
- 239000003018 immunosuppressive agent Substances 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 208000019423 liver disease Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 201000000050 myeloid neoplasm Diseases 0.000 claims 1
- 208000015122 neurodegenerative disease Diseases 0.000 claims 1
- 239000003900 neurotrophic factor Substances 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
- 239000003981 vehicle Substances 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US87487806P | 2006-12-14 | 2006-12-14 | |
| US60/874,878 | 2006-12-14 | ||
| PCT/US2007/025688 WO2008076392A2 (en) | 2006-12-14 | 2007-12-14 | Compounds useful as protein kinase inhibitors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2010513285A JP2010513285A (ja) | 2010-04-30 |
| JP2010513285A5 true JP2010513285A5 (enExample) | 2011-04-14 |
| JP5406725B2 JP5406725B2 (ja) | 2014-02-05 |
Family
ID=39323721
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009541404A Expired - Fee Related JP5406725B2 (ja) | 2006-12-14 | 2007-12-14 | タンパク質キナーゼ阻害剤として有用な化合物 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US8129387B2 (enExample) |
| EP (1) | EP2102210B1 (enExample) |
| JP (1) | JP5406725B2 (enExample) |
| CN (1) | CN101646671A (enExample) |
| AT (1) | ATE497961T1 (enExample) |
| AU (1) | AU2007334379B2 (enExample) |
| CA (1) | CA2672612A1 (enExample) |
| DE (1) | DE602007012473D1 (enExample) |
| ES (1) | ES2359467T3 (enExample) |
| MX (1) | MX2009006345A (enExample) |
| NZ (1) | NZ577638A (enExample) |
| WO (1) | WO2008076392A2 (enExample) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA95940C2 (uk) | 2006-01-17 | 2011-09-26 | Вертекс Фармасьютикалс Інкорпорейтед | Азаіндоли як інгібітори кіназ януса |
| JP2011515072A (ja) * | 2008-02-13 | 2011-05-19 | エラン ファーマ インターナショナル リミテッド | α−シヌクレインキナーゼ |
| MX2011000021A (es) | 2008-06-23 | 2011-02-24 | Vertex Pharma | Inhibidores de proteina cinasas. |
| AU2009271658B2 (en) | 2008-06-23 | 2014-04-10 | Vertex Pharmaceuticals Incorporated | Protein kinase inhibitors |
| WO2010025073A1 (en) * | 2008-08-28 | 2010-03-04 | Takeda Pharmaceutical Company Limited | Dihydroimidazo [ 1, 5-f] pteridines as polo-like kinase inhibitors |
| LT3141252T (lt) | 2009-06-17 | 2018-11-12 | Vertex Pharmaceuticals Inc. | Gripo virusų replikacijos inhibitoriai |
| RU2012131124A (ru) * | 2009-12-23 | 2014-01-27 | Элан Фармасьютикалз, Инк. | Птеридиноны как ингибиторы polo-подобных киназ |
| CN103403010A (zh) * | 2010-10-08 | 2013-11-20 | 依兰制药公司 | Polo样激酶的抑制剂 |
| RU2013132681A (ru) | 2010-12-16 | 2015-01-27 | Вертекс Фармасьютикалз Инкорпорейтед | Ингибиторы репликации вирусов гриппа |
| NZ714502A (en) | 2011-07-05 | 2017-04-28 | Vertex Pharma | Processes and intermediates for producing azaindoles |
| UA118010C2 (uk) | 2011-08-01 | 2018-11-12 | Вертекс Фармасьютікалз Інкорпорейтед | Інгібітори реплікації вірусів грипу |
| WO2014209978A1 (en) * | 2013-06-24 | 2014-12-31 | Merck Patent Gmbh | Imidazole compounds as modulators of fshr and uses thereof |
| JP6618901B2 (ja) | 2013-11-13 | 2019-12-11 | バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ | インフルエンザウイルスの複製の阻害剤を調製する方法 |
| LT3068776T (lt) | 2013-11-13 | 2019-08-12 | Vertex Pharmaceuticals Incorporated | Gripo virusų replikacijos inhibitoriai |
| US9840503B2 (en) | 2015-05-11 | 2017-12-12 | Incyte Corporation | Heterocyclic compounds and uses thereof |
| EP3294717B1 (en) | 2015-05-13 | 2020-07-29 | Vertex Pharmaceuticals Inc. | Methods of preparing inhibitors of influenza viruses replication |
| EP3294735B8 (en) | 2015-05-13 | 2022-01-05 | Vertex Pharmaceuticals Incorporated | Inhibitors of influenza viruses replication |
| US9708333B2 (en) | 2015-08-12 | 2017-07-18 | Incyte Corporation | Fused bicyclic 1,2,4-triazine compounds as TAM inhibitors |
| WO2017035366A1 (en) | 2015-08-26 | 2017-03-02 | Incyte Corporation | Pyrrolopyrimidine derivatives as tam inhibitors |
| KR102483020B1 (ko) | 2016-03-28 | 2023-01-04 | 인사이트 코포레이션 | Tam 저해제로서의 피롤로트리아진 화합물 |
| MA50655B1 (fr) | 2017-09-27 | 2021-11-30 | Incyte Corp | Sels de dérivés de pyrrolotriazine utiles en tant qu'inhibiteurs de tam |
| AR117600A1 (es) | 2018-06-29 | 2021-08-18 | Incyte Corp | Formulaciones de un inhibidor de axl / mer |
| CN111217815B (zh) * | 2018-11-27 | 2021-06-18 | 沈阳药科大学 | 含有喋啶酮骨架的化合物及其制备方法和应用 |
| WO2021178779A1 (en) | 2020-03-06 | 2021-09-10 | Incyte Corporation | Combination therapy comprising axl/mer and pd-1/pd-l1 inhibitors |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2322311C (en) * | 1998-03-04 | 2009-10-13 | Bristol-Myers Squibb Company | Heterocyclo-substituted imidazopyrazine protein tyrosine kinase inhibitors |
| JP3876265B2 (ja) * | 2003-02-26 | 2007-01-31 | ベーリンガー インゲルハイム ファルマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト | ジヒドロプテリジノン、その製造方法及び薬物形態での使用 |
| US20060058311A1 (en) | 2004-08-14 | 2006-03-16 | Boehringer Ingelheim International Gmbh | Combinations for the treatment of diseases involving cell proliferation |
| US20060074088A1 (en) | 2004-08-14 | 2006-04-06 | Boehringer Ingelheim International Gmbh | Dihydropteridinones for the treatment of cancer diseases |
| US7728134B2 (en) | 2004-08-14 | 2010-06-01 | Boehringer Ingelheim International Gmbh | Hydrates and polymorphs of 4[[(7R)-8-cyclopentyl-7-ethyl-5,6,7,8-tetrahydro-5-methyl-6-oxo-2-pteridinyl]amino]-3-methoxy-N-(1-methyl-4-piperidinyl)-benzamide, process for their manufacture and their use as medicament |
| GB0621203D0 (en) | 2006-10-25 | 2006-12-06 | Chroma Therapeutics Ltd | PLK inhibitors |
| EA200900593A1 (ru) | 2006-10-25 | 2010-06-30 | Хрома Терапьютикс Лтд. | Производные птеридина как ингибиторы polo-подобной киназы, применяющиеся при лечении рака |
| RU2339637C1 (ru) | 2007-04-05 | 2008-11-27 | Андрей Александрович Иващенко | Блокаторы гистаминного рецептора для фармацевтических композиций, обладающих противоаллергическим и аутоиммунным действием |
| UA98324C2 (ru) | 2007-04-05 | 2012-05-10 | Андрей Александрович Иващенко | ЗАМЕЩЕННЫЕ 2,3,4,5-ТЕТРАГИДРО-1H-ПИРИДО[4,3-b]ИНДОЛЫ, СПОСОБ ИХ ПОЛУЧЕНИЯ И ПРИМЕНЕНИЯ |
-
2007
- 2007-12-14 CN CN200780050825A patent/CN101646671A/zh active Pending
- 2007-12-14 AT AT07862967T patent/ATE497961T1/de not_active IP Right Cessation
- 2007-12-14 ES ES07862967T patent/ES2359467T3/es active Active
- 2007-12-14 NZ NZ577638A patent/NZ577638A/en not_active IP Right Cessation
- 2007-12-14 WO PCT/US2007/025688 patent/WO2008076392A2/en not_active Ceased
- 2007-12-14 DE DE602007012473T patent/DE602007012473D1/de active Active
- 2007-12-14 CA CA002672612A patent/CA2672612A1/en not_active Abandoned
- 2007-12-14 AU AU2007334379A patent/AU2007334379B2/en not_active Ceased
- 2007-12-14 MX MX2009006345A patent/MX2009006345A/es active IP Right Grant
- 2007-12-14 US US12/448,258 patent/US8129387B2/en not_active Expired - Fee Related
- 2007-12-14 JP JP2009541404A patent/JP5406725B2/ja not_active Expired - Fee Related
- 2007-12-14 EP EP07862967A patent/EP2102210B1/en not_active Not-in-force
-
2012
- 2012-01-24 US US13/356,924 patent/US8557818B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010513285A5 (enExample) | ||
| JP2009523822A5 (enExample) | ||
| JP2020528889A5 (enExample) | ||
| JP2009526849A5 (enExample) | ||
| RU2008144584A (ru) | 4,5-дигидро-[1,2,4]триазоло[4,3-f]птеридины в качестве ингибиторов протеинкиназы plk1 для лечения пролиферативных заболеваний | |
| JP2009536155A5 (enExample) | ||
| JP2020537501A5 (enExample) | ||
| RU2004138819A (ru) | Ингибиторы протеинкиназ jak и cdk2 | |
| RU2015124002A (ru) | Соединения, применяемые в качестве ингибиторов индоламин-2,3-диоксигеназы | |
| JP2016528197A5 (enExample) | ||
| JP2006508107A5 (enExample) | ||
| JP2010532380A5 (enExample) | ||
| JP2021502387A5 (enExample) | ||
| JP2010523522A5 (enExample) | ||
| RU2006138040A (ru) | Азаиндолы, полезные в качестве ингибиторов jak и других протеинкиназ | |
| JP2010538001A5 (enExample) | ||
| JP2018507877A5 (enExample) | ||
| JP2010520886A5 (enExample) | ||
| JP2013512903A5 (enExample) | ||
| JP2008545660A5 (enExample) | ||
| JP2009513703A5 (enExample) | ||
| JP2010501584A5 (enExample) | ||
| JP2009504764A5 (enExample) | ||
| JP2011510056A5 (enExample) | ||
| JP2010510216A5 (enExample) |